Cashu
Curis Advances AML Treatment with Promising Emavusertib Clinical Data at ASH Annual Meeting
20 days ago
Stocks
Health Care
cris
Curis
NASDAQ: CRIS
-0.02 (-2.27%)
0.9871
USD
At close at Jan 01, 16:35 UTC
Overview
Loading chart...
Key Stats
Market Cap
12.34M
Dividend Yield
0.00%
P/E Ratio
-0.34
EPS
-6.89
Revenue
10.91M
Avg. Volume
147.33K
About
What does CRIS do?
Curis, headquartered in Lexington, Massachusetts, focuses on developing cancer treatments, including emavusertib for various lymphomas and leukemias, alongside other candidates like Fimepinostat and CA-170. The company, which went public in 2000, employs 48 full-time staff.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.